Table 4 HHT Pharmacokinetic parameters

From: A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia

Dose

 

Cmax day 5 (ng ml−1)

T max day 5 (h)

Cmin day 5 (ng ml−1)

Cmin day 9 (ng ml−1)

AUC day 9 (ng h ml−1)

Vdβ/F (l kg−1)

CL/ F (l h−1)

T 1/2 (h)

mg m −2  day −1

mg

No. Pts

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

0.5

0.9–1.0

3

10.5

8.8

1.0

0.12

3.4

0.9

  

169

38

1.52

0.39

5.9

1.60

13.4

3.8

3

4.8–5.4

2

78.0

18.2

0.6

0.53

27.4

27.9

14.7

8.3

441

291

2.54

0.75

14.2

8.77

8.9

3.7

5

7.0–10.0

12

96.1

20.3

0.6

0.43

31.3

16.7

25.6

20.3

909

550

2.02

1.43

11.6

10.4

10.8

3.2

Grand mean

                

11.01

3.4*

  1. *P-value for Kruskall–Wallis test (P=0.52).